secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001683168-24-004526
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical reports FY2024 net loss of $12.2M; cash at $9.1M; oncology trial approved
--------------------------------------------------------------------------------

- Net loss of $12.2M for FY ended March 31, 2024, compared to $12.0M in FY2023.
- Cash balance of $5.4M at March 31, 2024, increased to $9.1M as of June 25, 2024.
- Received HREC ethics approval for Hemopurifier safety/feasibility oncology trial in Australia, valid through 2027.
- FDA approved internal manufacturing facility in April 2024.
- COVID-19 trial in India remains open with one patient treated; monitoring H5N1 avian flu situation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316824004526/0001683168-24-004526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316824004526/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-004526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer